J L Van Laethem
Overview
Explore the profile of J L Van Laethem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Islam O, Islam O, Sarti K, Sarti K, Verbruggen L, Verbruggen L, et al.
Endocr Relat Cancer
. 2025 Jan;
32(4).
PMID: 39888333
Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO subdivided the grade 3 (G3) neuroendocrine neoplasms (NEN) characterised by Ki-67 >...
2.
Van Laethem J, Bali M
United European Gastroenterol J
. 2024 Jul;
12(7):990-991.
PMID: 38970215
No abstract available.
3.
Ziane Bouziane S, Mans L, Bucalau A, Demetter P, Pezzullo M, Andre C, et al.
Eur J Cancer
. 2024 May;
206:114128.
PMID: 38805957
Duodenal adenocarcinoma is a rare digestive cancer, often diagnosed at a late stage and harbours a poor prognosis. The arrival of immunotherapy has changed the prognosis of many neoplasia, including...
4.
Mas L, Cros J, Svrcek M, Van Laethem J, Emile J, Rebours V, et al.
Clin Res Hepatol Gastroenterol
. 2023 Mar;
47(4):102108.
PMID: 36878461
Background: Trop-2 is overexpressed in tumor cells of various cancers, including pancreatic ductal adenocarcinoma (PDAC), and has emerged as a potent therapeutic target. We evaluated Trop-2 expression both at the...
5.
Nicolle R, Gayet O, Bigonnet M, Roques J, Chanez B, Puleo F, et al.
Transl Oncol
. 2021 Dec;
16:101315.
PMID: 34906890
Pancreatic ductal adenocarcinoma (PDAC) patients are frequently treated by chemotherapy. Even if personalized therapy based on molecular analysis can be performed for some tumors, PDAC regimens selection is still mainly...
6.
Figueiredo M, Arvanitakis M, Zaarour A, Toussaint E, Deviere J, Van Laethem J, et al.
Acta Gastroenterol Belg
. 2021 Oct;
84(3):451-455.
PMID: 34599570
Background And Aims: Endoscopic ultrasound fine-needle aspiration/biopsy (EUS-FNA/FNB) is highly accurate, but discrepancies between cytological and surgical diagnoses are still observed. We aimed to determine its accuracy and monitor quality...
7.
Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, et al.
Ann Oncol
. 2020 Nov;
32(2):250-260.
PMID: 33188873
Background: Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a...
8.
Martens S, Lefesvre P, Nicolle R, Biankin A, Puleo F, Van Laethem J, et al.
Ann Oncol
. 2019 Jun;
30(9):1428-1436.
PMID: 31161208
Background: Different histological and molecular subtypes of pancreatic ductal adenocarcinoma (PDAC), with different molecular composition and survival statistics, have recently been recognised. Materials And Methods: This review describes the currently...
9.
Gidron Y, De Couck M, Schallier D, De Greve J, Van Laethem J, Marechal R
J Immunol Res
. 2018 Jun;
2018:4874193.
PMID: 29854838
Background: The vagus nerve may slow tumor progression because it inhibits inflammation. This study examined the relationship between a new vagal neuroimmunomodulation (NIM) index and survival in fatal cancers. Method:...
10.
Taieb J, Pointet A, Van Laethem J, Laquente B, Pernot S, Lordick F, et al.
Ann Oncol
. 2017 May;
28(7):1473-1483.
PMID: 28459988
Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been...